drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01132 | DB01149 | 1,130 | 851 | [
"DDInter1472",
"DDInter1274"
] | Pioglitazone | Nefazodone | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
1130,
24,
851
]
],
[
[
1130,
63,
1178
],
[
1178,
1,
851
]
],
[
[
1130,
24,
673
],
[
673,
40,
851
]
],
[
[
1130,
6,
8374
],
[
8374,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodone (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Nefa... |
DB00270 | DB06292 | 1,428 | 549 | [
"DDInter993",
"DDInter474"
] | Isradipine | Dapagliflozin | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1428,
24,
549
]
],
[
[
1428,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
549
]
],
[
[
1428,
21,
28898
],
[
28898... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Isradipine (Compound) causes Constipation (Side Effect... |
DB09498 | DB15699 | 810 | 652 | [
"DDInter1715",
"DDInter232"
] | Strontium chloride Sr-89 | Brexucabtagene autoleucel | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Moderate | 1 | [
[
[
810,
24,
652
]
],
[
[
810,
63,
4
],
[
4,
24,
652
]
],
[
[
810,
24,
738
],
[
738,
24,
652
]
],
[
[
810,
63,
976
],
[
976,
25,
... | [
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Strontium chloride Sr-89 may cause a moderate interac... |
DB00444 | DB14723 | 63 | 159 | [
"DDInter1765",
"DDInter1026"
] | Teniposide | Larotrectinib | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
63,
24,
159
]
],
[
[
63,
24,
1375
],
[
1375,
24,
159
]
],
[
[
63,
23,
307
],
[
307,
24,
159
]
],
[
[
63,
35,
896
],
[
896,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Teniposide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafini... |
DB00515 | DB08901 | 589 | 1,468 | [
"DDInter387",
"DDInter1492"
] | Cisplatin | Ponatinib | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
589,
24,
1468
]
],
[
[
589,
6,
17404
],
[
17404,
45,
1468
]
],
[
[
589,
6,
2350
],
[
2350,
57,
1468
]
],
[
[
589,
21,
28852
],
[
28852... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Cisplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ponatinib (Compound)
Cisplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Ponatinib (Compound)
Cisplatin (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Cisplatin may caus... |
DB00382 | DB00804 | 62 | 1,507 | [
"DDInter1734",
"DDInter543"
] | Tacrine | Dicyclomine | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
62,
24,
1507
]
],
[
[
62,
63,
1594
],
[
1594,
24,
1507
]
],
[
[
62,
24,
543
],
[
543,
63,
1507
]
],
[
[
62,
24,
19
],
[
19,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide ... |
DB00364 | DB00477 | 417 | 216 | [
"DDInter1717",
"DDInter363"
] | Sucralfate | Chlorpromazine | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Minor | 0 | [
[
[
417,
23,
216
]
],
[
[
417,
23,
1178
],
[
1178,
1,
216
]
],
[
[
417,
23,
684
],
[
684,
40,
216
]
],
[
[
417,
6,
1829
],
[
1829,
4... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trifluoperazine"
],
... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpro... |
DB01073 | DB12674 | 1,488 | 975 | [
"DDInter745",
"DDInter1105"
] | Fludarabine | Lurbinectedin | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1488,
24,
975
]
],
[
[
1488,
40,
372
],
[
372,
24,
975
]
],
[
[
1488,
24,
980
],
[
980,
24,
975
]
],
[
[
1488,
63,
147
],
[
147,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a ... | Fludarabine (Compound) resembles Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction t... |
DB00655 | DB06655 | 559 | 5 | [
"DDInter682",
"DDInter1077"
] | Estrone | Liraglutide | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
559,
24,
5
]
],
[
[
559,
63,
353
],
[
353,
23,
5
]
],
[
[
559,
24,
870
],
[
870,
24,
5
]
],
[
[
559,
63,
245
],
[
245,
24,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
... | Estrone may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Flud... |
DB01110 | DB08895 | 86 | 976 | [
"DDInter1209",
"DDInter1825"
] | Miconazole | Tofacitinib | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
86,
24,
976
]
],
[
[
86,
62,
307
],
[
307,
23,
976
]
],
[
[
86,
24,
214
],
[
214,
63,
976
]
],
[
[
86,
63,
723
],
[
723,
24,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Miconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamati... |
DB00023 | DB00603 | 305 | 303 | [
"DDInter127",
"DDInter1137"
] | Asparaginase Escherichia coli | Medroxyprogesterone acetate | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
305,
24,
303
]
],
[
[
305,
24,
167
],
[
167,
1,
303
]
],
[
[
305,
24,
1561
],
[
1561,
40,
303
]
],
[
[
305,
24,
700
],
[
700,
62... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases w... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Testos... |
DB11730 | DB12267 | 351 | 1,476 | [
"DDInter1588",
"DDInter233"
] | Ribociclib | Brigatinib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
351,
25,
1476
]
],
[
[
351,
25,
1612
],
[
1612,
23,
1476
]
],
[
[
351,
64,
1135
],
[
1135,
23,
1476
]
],
[
[
351,
63,
629
],
[
629,
... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u}... | Ribociclib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ribociclib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interacti... |
DB08827 | DB11767 | 990 | 1,583 | [
"DDInter1085",
"DDInter1643"
] | Lomitapide | Sarilumab | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Major | 2 | [
[
[
990,
25,
1583
]
],
[
[
990,
64,
267
],
[
267,
24,
1583
]
],
[
[
990,
25,
850
],
[
850,
24,
1583
]
],
[
[
990,
63,
1409
],
[
1409,
... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} ma... | Lomitapide may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Lomitapide may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may caus... |
DB01075 | DB03128 | 1,376 | 140 | [
"DDInter569",
"DDInter18"
] | Diphenhydramine | Acetylcholine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken ... | Moderate | 1 | [
[
[
1376,
24,
140
]
],
[
[
1376,
63,
999
],
[
999,
24,
140
]
],
[
[
1376,
24,
1415
],
[
1415,
24,
140
]
],
[
[
1376,
35,
272
],
[
272,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylcholine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazi... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00005 | DB00609 | 1,057 | 595 | [
"DDInter687",
"DDInter694"
] | Etanercept | Ethionamide | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Moderate | 1 | [
[
[
1057,
24,
595
]
],
[
[
1057,
25,
372
],
[
372,
63,
595
]
],
[
[
1057,
24,
597
],
[
597,
24,
595
]
],
[
[
1057,
24,
112
],
[
112,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clofarab... | Etanercept may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenic... |
DB06292 | DB09128 | 549 | 1,241 | [
"DDInter474",
"DDInter231"
] | Dapagliflozin | Brexpiprazole | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
549,
24,
1241
]
],
[
[
549,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
549,
63,
1179
],
[
1179,
24,
1241
]
],
[
[
549,
1,
1344
],
[
1344,
... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00526 | DB06643 | 1,555 | 1,136 | [
"DDInter1355",
"DDInter500"
] | Oxaliplatin | Denosumab | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1555,
24,
1136
]
],
[
[
1555,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
1555,
63,
1648
],
[
1648,
24,
1136
]
],
[
[
1555,
24,
1480
],
[
14... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesl... |
DB00748 | DB00899 | 662 | 411 | [
"DDInter297",
"DDInter1579"
] | Carbinoxamine | Remifentanil | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Moderate | 1 | [
[
[
662,
24,
411
]
],
[
[
662,
24,
1322
],
[
1322,
40,
411
]
],
[
[
662,
24,
704
],
[
704,
1,
411
]
],
[
[
662,
63,
1454
],
[
1454,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Comp... |
DB00001 | DB01242 | 1,578 | 1,237 | [
"DDInter1037",
"DDInter410"
] | Lepirudin | Clomipramine | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1578,
24,
1237
]
],
[
[
1578,
24,
1274
],
[
1274,
24,
1237
]
],
[
[
1578,
25,
498
],
[
498,
63,
1237
]
],
[
[
1578,
25,
1347
],
[
1347... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Lepirudin may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause ... |
DB01246 | DB04844 | 820 | 843 | [
"DDInter45",
"DDInter1778"
] | Alimemazine | Tetrabenazine | A phenothiazine derivative that is used as an antipruritic. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Major | 2 | [
[
[
820,
25,
843
]
],
[
[
820,
63,
479
],
[
479,
40,
843
]
],
[
[
820,
21,
28698
],
[
28698,
60,
843
]
],
[
[
820,
62,
112
],
[
112,
... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepe... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Alimemazine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Alimemazine may cause a minor interactio... |
DB00043 | DB00163 | 1,504 | 1,461 | [
"DDInter1337",
"DDInter1943"
] | Omalizumab | Vitamin E | Omalizumab, manufactured by _Genentech_, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been ... | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Minor | 0 | [
[
[
1504,
23,
1461
]
],
[
[
1504,
23,
1193
],
[
1193,
62,
1096
],
[
1096,
62,
1461
]
],
[
[
1504,
23,
1114
],
[
1114,
62,
66
],
[
66,
23... | [
[
[
"Omalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Omalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Omalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with V... |
DB01064 | DB04953 | 1,148 | 495 | [
"DDInter987",
"DDInter708"
] | Isoprenaline | Ezogabine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
1148,
24,
495
]
],
[
[
1148,
21,
28695
],
[
28695,
60,
495
]
],
[
[
1148,
63,
1494
],
[
1494,
24,
495
]
],
[
[
1148,
24,
927
],
[
927,... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is cau... | Isoprenaline (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Ezogabine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ez... |
DB00776 | DB01166 | 1,335 | 477 | [
"DDInter1360",
"DDInter379"
] | Oxcarbazepine | Cilostazol | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1335,
24,
477
]
],
[
[
1335,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1335,
21,
30397
],
[
30397,
60,
477
]
],
[
[
1335,
40,
126
],
[
126,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Oxcarbazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Oxcarbazepine (Compound) causes Drug eruption (Side Effect) and Drug eruption (Side Effect) is caused by Cilostazol (Compound)
Oxcarbazepine (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interactio... |
DB00776 | DB12141 | 1,335 | 971 | [
"DDInter1360",
"DDInter817"
] | Oxcarbazepine | Gilteritinib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1335,
24,
971
]
],
[
[
1335,
24,
1135
],
[
1135,
23,
971
]
],
[
[
1335,
24,
466
],
[
466,
62,
971
]
],
[
[
1335,
63,
1181
],
[
1181,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and ... |
DB01115 | DB11581 | 336 | 1,456 | [
"DDInter1291",
"DDInter1926"
] | Nifedipine | Venetoclax | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
336,
25,
1456
]
],
[
[
336,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
336,
24,
259
],
[
259,
24,
1456
]
],
[
[
336,
24,
1476
],
[
1476,
... | [
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Nifedipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept m... |
DB05239 | DB12010 | 866 | 214 | [
"DDInter425",
"DDInter785"
] | Cobimetinib | Fostamatinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
866,
24,
214
]
],
[
[
866,
25,
976
],
[
976,
24,
214
]
],
[
[
866,
64,
723
],
[
723,
24,
214
]
],
[
[
866,
63,
322
],
[
322,
24,... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofac... | Cobimetinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cobimetinib may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderat... |
DB00902 | DB01255 | 104 | 633 | [
"DDInter1168",
"DDInter1078"
] | Methdilazine | Lisdexamfetamine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
104,
24,
633
]
],
[
[
104,
63,
551
],
[
551,
1,
633
]
],
[
[
104,
63,
80
],
[
80,
40,
633
]
],
[
[
104,
24,
1529
],
[
1529,
1,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfe... |
DB00459 | DB00563 | 640 | 663 | [
"DDInter21",
"DDInter1174"
] | Acitretin | Methotrexate | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Major | 2 | [
[
[
640,
25,
663
]
],
[
[
640,
5,
11587
],
[
11587,
44,
663
]
],
[
[
640,
6,
1829
],
[
1829,
45,
663
]
],
[
[
640,
21,
28681
],
[
28681,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Acitretin",
"{u} (Compound) treats {v} (Disease)",
"psoriasis"
],
[
"psoriasis",
"{u} (Disease) is treated by {v} (Compound)",... | Acitretin (Compound) treats psoriasis (Disease) and psoriasis (Disease) is treated by Methotrexate (Compound)
Acitretin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Methotrexate (Compound)
Acitretin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (... |
DB04865 | DB10989 | 4 | 496 | [
"DDInter1335",
"DDInter858"
] | Omacetaxine mepesuccinate | Hepatitis A Vaccine | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
4,
24,
496
]
],
[
[
4,
24,
1093
],
[
1093,
63,
496
]
],
[
[
4,
24,
850
],
[
850,
24,
496
]
],
[
[
4,
63,
147
],
[
147,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate disease... |
DB00060 | DB06186 | 912 | 1,439 | [
"DDInter947",
"DDInter969"
] | Interferon beta-1a | Ipilimumab | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
912,
24,
1439
]
],
[
[
912,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
912,
24,
482
],
[
482,
24,
1439
]
],
[
[
912,
63,
268
],
[
268,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargas... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when ... |
DB01024 | DB01326 | 1,096 | 1,124 | [
"DDInter1252",
"DDInter312"
] | Mycophenolic acid | Cefamandole | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. It is no longer marketed in the United States. | Moderate | 1 | [
[
[
1096,
24,
1124
]
],
[
[
1096,
63,
1305
],
[
1305,
1,
1124
]
],
[
[
1096,
24,
1227
],
[
1227,
1,
1124
]
],
[
[
1096,
24,
665
],
[
665,
... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefaclor"
... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefaclor and Cefaclor (Compound) resembles Cefamandole (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefazolin and Cefazolin (Compound) resembles Cefamandole (... |
DB01072 | DB12001 | 915 | 564 | [
"DDInter129",
"DDInter7"
] | Atazanavir | Abemaciclib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
915,
25,
564
]
],
[
[
915,
63,
1051
],
[
1051,
24,
564
]
],
[
[
915,
24,
868
],
[
868,
24,
564
]
],
[
[
915,
25,
392
],
[
392,
2... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Am... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Vemura... |
DB01227 | DB11901 | 1,301 | 913 | [
"DDInter1043",
"DDInter107"
] | Levacetylmethadol | Apalutamide | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1301,
25,
913
]
],
[
[
1301,
62,
112
],
[
112,
23,
913
]
],
[
[
1301,
64,
600
],
[
600,
24,
913
]
],
[
[
1301,
24,
28
],
[
28,
2... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Levacetylmethadol may lead to a major life threatening interaction when taken with Fluconazole and Flu... |
DB01234 | DB08903 | 1,220 | 996 | [
"DDInter513",
"DDInter170"
] | Dexamethasone | Bedaquiline | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1220,
25,
996
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1220,
21,
29282
],
[
29282,
60,
996
]
],
[
[
1220,
24,
713
],
[
713,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"... | Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Dexamethasone (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dimeth... |
DB00748 | DB00765 | 662 | 1,266 | [
"DDInter297",
"DDInter1205"
] | Carbinoxamine | Metyrosine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Moderate | 1 | [
[
[
662,
24,
1266
]
],
[
[
662,
21,
28762
],
[
28762,
60,
1266
]
],
[
[
662,
24,
401
],
[
401,
63,
1266
]
],
[
[
662,
35,
649
],
[
649,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrosine"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is ... | Carbinoxamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Metyrosine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00782 | DB01148 | 1,123 | 1,128 | [
"DDInter1535",
"DDInter738"
] | Propantheline | Flavoxate | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
1123,
24,
1128
]
],
[
[
1123,
6,
7992
],
[
7992,
45,
1128
]
],
[
[
1123,
21,
28769
],
[
28769,
60,
1128
]
],
[
[
1123,
24,
537
],
[
53... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Propantheline",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound... | Propantheline (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Flavoxate (Compound)
Propantheline (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flavoxate (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01069 | DB01200 | 401 | 469 | [
"DDInter1533",
"DDInter243"
] | Promethazine | Bromocriptine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
401,
24,
469
]
],
[
[
401,
6,
4228
],
[
4228,
45,
469
]
],
[
[
401,
21,
28787
],
[
28787,
60,
469
]
],
[
[
401,
63,
888
],
[
888,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"HTR2A"
],
[
"HTR2A",
"{u} (Gene) is bound by {v} (Compou... | Promethazine (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Bromocriptine (Compound)
Promethazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxif... |
DB00106 | DB00674 | 618 | 1,516 | [
"DDInter4",
"DDInter802"
] | Abarelix | Galantamine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Moderate | 1 | [
[
[
618,
24,
1516
]
],
[
[
618,
24,
688
],
[
688,
63,
1516
]
],
[
[
618,
25,
57
],
[
57,
63,
1516
]
],
[
[
618,
24,
1494
],
[
1494,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Galantamine"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Galantamine
Abarelix may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide m... |
DB00398 | DB12095 | 79 | 179 | [
"DDInter1702",
"DDInter1760"
] | Sorafenib | Telotristat ethyl | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
79,
24,
179
]
],
[
[
79,
24,
310
],
[
310,
24,
179
]
],
[
[
79,
25,
1493
],
[
1493,
24,
179
]
],
[
[
79,
63,
1010
],
[
1010,
24,... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Sorafenib may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine... |
DB00629 | DB00902 | 390 | 104 | [
"DDInter844",
"DDInter1168"
] | Guanabenz | Methdilazine | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
390,
24,
104
]
],
[
[
390,
24,
820
],
[
820,
1,
104
]
],
[
[
390,
24,
401
],
[
401,
63,
104
]
],
[
[
390,
63,
530
],
[
530,
24,
... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that... |
DB00978 | DB08907 | 739 | 1,344 | [
"DDInter1084",
"DDInter280"
] | Lomefloxacin | Canagliflozin | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
739,
24,
1344
]
],
[
[
739,
24,
549
],
[
549,
1,
1344
]
],
[
[
739,
6,
5912
],
[
5912,
45,
1344
]
],
[
[
739,
21,
28681
],
[
28681,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Lomefloxacin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound)
Lomefloxacin (Compound) causes Hypersensitivity (Sid... |
DB00342 | DB06402 | 1,181 | 1,079 | [
"DDInter1770",
"DDInter1756"
] | Terfenadine | Telavancin | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
1181,
24,
1079
]
],
[
[
1181,
23,
112
],
[
112,
23,
1079
]
],
[
[
1181,
24,
657
],
[
657,
63,
1079
]
],
[
[
1181,
24,
543
],
[
543,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Ca... |
DB01142 | DB05381 | 1,264 | 172 | [
"DDInter593",
"DDInter863"
] | Doxepin | Histamine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
1264,
24,
172
]
],
[
[
1264,
35,
1237
],
[
1237,
24,
172
]
],
[
[
1264,
63,
1242
],
[
1242,
24,
172
]
],
[
[
1264,
24,
337
],
[
337,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Doxepin (Compound) resembles Clomipramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Doxepin may cause a moderate interaction that could exa... |
DB00615 | DB12010 | 690 | 214 | [
"DDInter1589",
"DDInter785"
] | Rifabutin | Fostamatinib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
690,
24,
214
]
],
[
[
690,
24,
976
],
[
976,
24,
214
]
],
[
[
690,
25,
866
],
[
866,
24,
214
]
],
[
[
690,
63,
10
],
[
10,
24,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Rifabutin may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may ca... |
DB00279 | DB01118 | 1,152 | 33 | [
"DDInter1074",
"DDInter76"
] | Liothyronine | Amiodarone | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
1152,
24,
33
]
],
[
[
1152,
6,
2021
],
[
2021,
45,
33
]
],
[
[
1152,
21,
29170
],
[
29170,
60,
33
]
],
[
[
1152,
24,
1419
],
[
1419,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Liothyronine",
"{u} (Compound) binds {v} (Gene)",
"THRB"
],
[
"THRB",
"{u} (Gene) is bound by {v} (Compound)",... | Liothyronine (Compound) binds THRB (Gene) and THRB (Gene) is bound by Amiodarone (Compound)
Liothyronine (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Amiodarone (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases... |
DB00087 | DB00848 | 599 | 281 | [
"DDInter41",
"DDInter1044"
] | Alemtuzumab | Levamisole | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Moderate | 1 | [
[
[
599,
24,
281
]
],
[
[
599,
24,
1683
],
[
1683,
63,
281
]
],
[
[
599,
24,
597
],
[
597,
24,
281
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamisole"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol a... |
DB06699 | DB08881 | 774 | 868 | [
"DDInter493",
"DDInter1925"
] | Degarelix | Vemurafenib | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
774,
25,
868
]
],
[
[
774,
21,
28847
],
[
28847,
60,
868
]
],
[
[
774,
63,
479
],
[
479,
23,
868
]
],
[
[
774,
62,
112
],
[
112,
... | [
[
[
"Degarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Degarelix",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} ... | Degarelix (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Vemura... |
DB00758 | DB06204 | 1,347 | 768 | [
"DDInter413",
"DDInter1746"
] | Clopidogrel | Tapentadol | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
1347,
24,
768
]
],
[
[
1347,
6,
10215
],
[
10215,
45,
768
]
],
[
[
1347,
21,
28692
],
[
28692,
60,
768
]
],
[
[
1347,
24,
578
],
[
578... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Clopidogrel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compoun... | Clopidogrel (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tapentadol (Compound)
Clopidogrel (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ti... |
DB00705 | DB06616 | 441 | 594 | [
"DDInter496",
"DDInter224"
] | Delavirdine | Bosutinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
441,
25,
594
]
],
[
[
441,
63,
883
],
[
883,
1,
594
]
],
[
[
441,
6,
8374
],
[
8374,
45,
594
]
],
[
[
441,
21,
28966
],
[
28966,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib"... | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Delavirdine (Compound) causes Upper respiratory tract infection (Sid... |
DB06595 | DB08895 | 1,491 | 976 | [
"DDInter1214",
"DDInter1825"
] | Midostaurin | Tofacitinib | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1491,
25,
976
]
],
[
[
1491,
63,
307
],
[
307,
23,
976
]
],
[
[
1491,
24,
214
],
[
214,
63,
976
]
],
[
[
1491,
25,
982
],
[
982,
... | [
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafini... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fosta... |
DB11113 | DB11718 | 657 | 927 | [
"DDInter307",
"DDInter640"
] | Castor oil | Encorafenib | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of, which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic,... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
657,
24,
927
]
],
[
[
657,
63,
216
],
[
216,
24,
927
]
],
[
[
657,
24,
938
],
[
938,
24,
927
]
],
[
[
657,
24,
484
],
[
484,
63,... | [
[
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
... | Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant a... |
DB11817 | DB15233 | 1,259 | 1,650 | [
"DDInter165",
"DDInter142"
] | Baricitinib | Avapritinib | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1259,
25,
1650
]
],
[
[
1259,
64,
1101
],
[
1101,
24,
1650
]
],
[
[
1259,
25,
270
],
[
270,
24,
1650
]
],
[
[
1259,
63,
810
],
[
810,
... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u... | Baricitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Baricitinib may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate... |
DB00526 | DB09498 | 1,555 | 810 | [
"DDInter1355",
"DDInter1715"
] | Oxaliplatin | Strontium chloride Sr-89 | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
1555,
24,
810
]
],
[
[
1555,
63,
552
],
[
552,
24,
810
]
],
[
[
1555,
24,
60
],
[
60,
24,
810
]
],
[
[
1555,
24,
1060
],
[
1060,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Capec... |
DB00254 | DB00417 | 964 | 1,667 | [
"DDInter598",
"DDInter1445"
] | Doxycycline | Phenoxymethylpenicillin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or [benzylpenicillin]. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, s... | Moderate | 1 | [
[
[
964,
24,
1667
]
],
[
[
964,
24,
1366
],
[
1366,
1,
1667
]
],
[
[
964,
24,
1681
],
[
1681,
40,
1667
]
],
[
[
964,
1,
1572
],
[
1572,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenoxymethylpenicillin"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meticillin"
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Meticillin and Meticillin (Compound) resembles Phenoxymethylpenicillin (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mezlocillin and Mezlocillin (Compound) resembles Pheno... |
DB00001 | DB00682 | 1,578 | 126 | [
"DDInter1037",
"DDInter1951"
] | Lepirudin | Warfarin | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1578,
25,
126
]
],
[
[
1578,
23,
944
],
[
944,
62,
126
]
],
[
[
1578,
25,
477
],
[
477,
62,
126
]
],
[
[
1578,
24,
557
],
[
557,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Warfarin
Lepirudin may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a minor in... |
DB01218 | DB08864 | 1,493 | 786 | [
"DDInter852",
"DDInter1595"
] | Halofantrine | Rilpivirine | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Major | 2 | [
[
[
1493,
25,
786
]
],
[
[
1493,
24,
655
],
[
655,
1,
786
]
],
[
[
1493,
6,
8374
],
[
8374,
45,
786
]
],
[
[
1493,
21,
28762
],
[
28762,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etrav... | Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Halofantrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Halofantrine (Compound) causes Headache (Side Effect) and He... |
DB00209 | DB00372 | 352 | 999 | [
"DDInter1886",
"DDInter1793"
] | Trospium | Thiethylperazine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
352,
24,
999
]
],
[
[
352,
24,
17
],
[
17,
63,
999
]
],
[
[
352,
23,
359
],
[
359,
63,
999
]
],
[
[
352,
24,
1089
],
[
1089,
24,... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Trospium may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chloroth... |
DB08932 | DB12500 | 1,398 | 283 | [
"DDInter1111",
"DDInter714"
] | Macitentan | Fedratinib | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1398,
24,
283
]
],
[
[
1398,
24,
351
],
[
351,
23,
283
]
],
[
[
1398,
63,
1593
],
[
1593,
23,
283
]
],
[
[
1398,
63,
1419
],
[
1419,
... | [
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotin... |
DB05273 | DB15762 | 507 | 725 | [
"DDInter1638",
"DDInter1644"
] | Samarium (153Sm) lexidronam | Satralizumab | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Major | 2 | [
[
[
507,
25,
725
]
],
[
[
507,
25,
1362
],
[
1362,
24,
725
]
],
[
[
507,
64,
372
],
[
372,
24,
725
]
],
[
[
507,
24,
270
],
[
270,
2... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Clofarabine and Clo... |
DB00211 | DB00816 | 1,290 | 1,674 | [
"DDInter1213",
"DDInter1346"
] | Midodrine | Orciprenaline | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
1290,
24,
1674
]
],
[
[
1290,
24,
874
],
[
874,
24,
1674
]
],
[
[
1290,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
1290,
24,
870
],
[
870... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Midodrine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (... |
DB00418 | DB11581 | 536 | 1,456 | [
"DDInter1650",
"DDInter1926"
] | Secobarbital | Venetoclax | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
536,
24,
1456
]
],
[
[
536,
24,
1135
],
[
1135,
23,
1456
]
],
[
[
536,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
536,
23,
752
],
[
752,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigat... |
DB00446 | DB00834 | 597 | 932 | [
"DDInter351",
"DDInter1215"
] | Chloramphenicol | Mifepristone | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
597,
24,
932
]
],
[
[
597,
6,
7524
],
[
7524,
45,
932
]
],
[
[
597,
7,
3466
],
[
3466,
46,
932
]
],
[
[
597,
18,
10780
],
[
10780,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} ... | Chloramphenicol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Chloramphenicol (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Mifepristone (Compound)
Chloramphenicol (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Mifepristone (Com... |
DB01041 | DB01229 | 770 | 973 | [
"DDInter1789",
"DDInter1377"
] | Thalidomide | Paclitaxel | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Major | 2 | [
[
[
770,
25,
973
]
],
[
[
770,
24,
310
],
[
310,
63,
973
]
],
[
[
770,
6,
7524
],
[
7524,
45,
973
]
],
[
[
770,
7,
2958
],
[
2958,
4... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazit... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Thalidomide (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Thalidomide (C... |
DB01359 | DB11093 | 729 | 636 | [
"DDInter1417",
"DDInter273"
] | Penbutolol | Calcium citrate | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
729,
24,
636
]
],
[
[
729,
62,
542
],
[
542,
24,
636
]
],
[
[
729,
1,
699
],
[
699,
24,
636
]
],
[
[
729,
40,
461
],
[
461,
24,
... | [
[
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Penbutolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levothyroxine"
],
... | Penbutolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Penbutolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that co... |
DB00945 | DB01377 | 1,479 | 1,283 | [
"DDInter20",
"DDInter1119"
] | Acetylsalicylic acid | Magnesium oxide | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1479,
24,
1283
]
],
[
[
1479,
63,
743
],
[
743,
23,
1283
]
],
[
[
1479,
62,
461
],
[
461,
23,
1283
]
],
[
[
1479,
23,
1592
],
[
1592,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Li... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with ... |
DB04946 | DB09291 | 924 | 741 | [
"DDInter907",
"DDInter1615"
] | Iloperidone | Rolapitant | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
924,
24,
741
]
],
[
[
924,
63,
506
],
[
506,
24,
741
]
],
[
[
924,
24,
159
],
[
159,
63,
741
]
],
[
[
924,
64,
1264
],
[
1264,
2... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
... | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Larotre... |
DB00569 | DB00749 | 553 | 59 | [
"DDInter775",
"DDInter699"
] | Fondaparinux | Etodolac | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Major | 2 | [
[
[
553,
25,
59
]
],
[
[
553,
21,
28748
],
[
28748,
60,
59
]
],
[
[
553,
64,
25
],
[
25,
24,
59
]
],
[
[
553,
24,
1039
],
[
1039,
63... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etodolac"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compou... | Fondaparinux (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Etodolac (Compound)
Fondaparinux may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Fondaparinu... |
DB00446 | DB06317 | 597 | 1,626 | [
"DDInter351",
"DDInter630"
] | Chloramphenicol | Elotuzumab | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
597,
24,
1626
]
],
[
[
597,
24,
973
],
[
973,
24,
1626
]
],
[
[
597,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
597,
24,
310
],
[
310,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin ... |
DB00370 | DB06603 | 1,251 | 39 | [
"DDInter1230",
"DDInter1387"
] | Mirtazapine | Panobinostat | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1251,
25,
39
]
],
[
[
1251,
23,
112
],
[
112,
23,
39
]
],
[
[
1251,
24,
272
],
[
272,
24,
39
]
],
[
[
1251,
25,
506
],
[
506,
24... | [
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Mirtazapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramin... |
DB05015 | DB11817 | 1,077 | 1,259 | [
"DDInter174",
"DDInter165"
] | Belinostat | Baricitinib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1077,
25,
1259
]
],
[
[
1077,
24,
949
],
[
949,
24,
1259
]
],
[
[
1077,
63,
563
],
[
563,
24,
1259
]
],
[
[
1077,
24,
1129
],
[
1129,
... | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formal... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Belinostat ... |
DB12010 | DB14840 | 214 | 861 | [
"DDInter785",
"DDInter1601"
] | Fostamatinib | Ripretinib | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
214,
24,
861
]
],
[
[
214,
63,
351
],
[
351,
24,
861
]
],
[
[
214,
24,
1017
],
[
1017,
24,
861
]
],
[
[
214,
64,
384
],
[
384,
2... | [
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lo... |
DB01589 | DB12500 | 481 | 283 | [
"DDInter1552",
"DDInter714"
] | Quazepam | Fedratinib | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
481,
24,
283
]
],
[
[
481,
63,
401
],
[
401,
24,
283
]
],
[
[
481,
24,
98
],
[
98,
24,
283
]
],
[
[
481,
40,
1382
],
[
1382,
24,... | [
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem... |
DB06237 | DB08865 | 438 | 1,593 | [
"DDInter141",
"DDInter448"
] | Avanafil | Crizotinib | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
438,
25,
1593
]
],
[
[
438,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
438,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
438,
25,
283
],
[
283,
... | [
[
[
"Avanafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Avanafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"... | Avanafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Avanafil (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Avanafil may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor ... |
DB00108 | DB00526 | 1,066 | 1,555 | [
"DDInter1268",
"DDInter1355"
] | Natalizumab | Oxaliplatin | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
1066,
25,
1555
]
],
[
[
1066,
25,
141
],
[
141,
24,
1555
]
],
[
[
1066,
24,
1136
],
[
1136,
63,
1555
]
],
[
[
1066,
25,
1213
],
[
1213... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"... | Natalizumab may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cau... |
DB00794 | DB12010 | 759 | 214 | [
"DDInter1521",
"DDInter785"
] | Primidone | Fostamatinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
759,
25,
214
]
],
[
[
759,
25,
976
],
[
976,
24,
214
]
],
[
[
759,
63,
723
],
[
723,
24,
214
]
],
[
[
759,
24,
973
],
[
973,
24,... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u}... | Primidone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may caus... |
DB00641 | DB14761 | 467 | 242 | [
"DDInter1675",
"DDInter1578"
] | Simvastatin | Remdesivir | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
467,
24,
242
]
],
[
[
467,
25,
1377
],
[
1377,
24,
242
]
],
[
[
467,
24,
129
],
[
129,
24,
242
]
],
[
[
467,
63,
482
],
[
482,
2... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Lefluno... | Simvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide ma... |
DB01222 | DB06186 | 617 | 1,439 | [
"DDInter246",
"DDInter969"
] | Budesonide | Ipilimumab | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
617,
24,
1439
]
],
[
[
617,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
617,
40,
1486
],
[
1486,
24,
1439
]
],
[
[
617,
63,
1560
],
[
1560,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
... | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Budesonide (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a... |
DB00108 | DB00987 | 1,066 | 1,224 | [
"DDInter1268",
"DDInter460"
] | Natalizumab | Cytarabine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Major | 2 | [
[
[
1066,
25,
1224
]
],
[
[
1066,
25,
1426
],
[
1426,
1,
1224
]
],
[
[
1066,
25,
322
],
[
322,
24,
1224
]
],
[
[
1066,
24,
987
],
[
987,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{... | Natalizumab may lead to a major life threatening interaction when taken with Azacitidine and Azacitidine (Compound) resembles Cytarabine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when ... |
DB10989 | DB11569 | 496 | 1,093 | [
"DDInter858",
"DDInter1003"
] | Hepatitis A Vaccine | Ixekizumab | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
496,
24,
1093
]
],
[
[
496,
63,
66
],
[
66,
24,
1093
]
],
[
[
496,
24,
270
],
[
270,
63,
1093
]
],
[
[
496,
63,
1057
],
[
1057,
... | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizuma... | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocr... |
DB00196 | DB11901 | 600 | 913 | [
"DDInter743",
"DDInter107"
] | Fluconazole | Apalutamide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
600,
24,
913
]
],
[
[
600,
25,
312
],
[
312,
23,
913
]
],
[
[
600,
23,
112
],
[
112,
23,
913
]
],
[
[
600,
24,
608
],
[
608,
23,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Epleren... | Fluconazole may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may c... |
DB01024 | DB10429 | 1,096 | 200 | [
"DDInter1252",
"DDInter282"
] | Mycophenolic acid | Candida albicans | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1096,
24,
200
]
],
[
[
1096,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1096,
25,
976
],
[
976,
24,
200
]
],
[
[
1096,
63,
1184
],
[
1184,
... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekin... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Mycophenolic acid may lead to a major life threatening interaction when taken with Tofacitinib an... |
DB00363 | DB01268 | 695 | 1,151 | [
"DDInter419",
"DDInter1731"
] | Clozapine | Sunitinib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Major | 2 | [
[
[
695,
25,
1151
]
],
[
[
695,
25,
1311
],
[
1311,
1,
1151
]
],
[
[
695,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
695,
23,
112
],
[
112,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"... | Clozapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Clozapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Clozapine may cause a minor interaction that can limit clinical effects when ta... |
DB01114 | DB01563 | 272 | 680 | [
"DDInter362",
"DDInter349"
] | Chlorpheniramine | Chloral hydrate | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
272,
24,
680
]
],
[
[
272,
63,
1614
],
[
1614,
24,
680
]
],
[
[
272,
24,
593
],
[
593,
24,
680
]
],
[
[
272,
74,
100
],
[
100,
2... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Bupropio... |
DB00278 | DB14006 | 291 | 972 | [
"DDInter117",
"DDInter370"
] | Argatroban | Choline salicylate | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
291,
24,
972
]
],
[
[
291,
25,
553
],
[
553,
24,
972
]
],
[
[
291,
24,
885
],
[
885,
24,
972
]
],
[
[
291,
64,
1255
],
[
1255,
2... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"... | Argatroban may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epopros... |
DB01250 | DB09133 | 712 | 1,527 | [
"DDInter1334",
"DDInter965"
] | Olsalazine | Iothalamic acid | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
712,
25,
1527
]
],
[
[
712,
24,
242
],
[
242,
63,
1527
]
],
[
[
712,
63,
589
],
[
589,
25,
1527
]
],
[
[
712,
24,
1329
],
[
1329,
... | [
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remde... | Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Ci... |
DB01191 | DB06081 | 1,039 | 1,046 | [
"DDInter518",
"DDInter286"
] | Dexfenfluramine | Caplacizumab | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
1039,
24,
1046
]
],
[
[
1039,
64,
222
],
[
222,
24,
1046
]
],
[
[
1039,
63,
1171
],
[
1171,
24,
1046
]
],
[
[
1039,
24,
885
],
[
885,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
... | Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxica... |
DB00633 | DB01105 | 614 | 222 | [
"DDInter520",
"DDInter1665"
] | Dexmedetomidine | Sibutramine | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
614,
24,
222
]
],
[
[
614,
6,
7390
],
[
7390,
45,
222
]
],
[
[
614,
21,
29152
],
[
29152,
60,
222
]
],
[
[
614,
63,
128
],
[
128,
... | [
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Dexmedetomidine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (... | Dexmedetomidine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Sibutramine (Compound)
Dexmedetomidine (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Sibutramine (Compound)
Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromp... |
DB00420 | DB06663 | 508 | 1,154 | [
"DDInter1532",
"DDInter1398"
] | Promazine | Pasireotide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
508,
25,
1154
]
],
[
[
508,
23,
112
],
[
112,
23,
1154
]
],
[
[
508,
24,
1385
],
[
1385,
63,
1154
]
],
[
[
508,
24,
170
],
[
170,
... | [
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Sema... |
DB00358 | DB00556 | 1,010 | 1,262 | [
"DDInter1140",
"DDInter1429"
] | Mefloquine | Perflutren | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Moderate | 1 | [
[
[
1010,
24,
1262
]
],
[
[
1010,
24,
679
],
[
679,
1,
1262
]
],
[
[
1010,
21,
29093
],
[
29093,
60,
1262
]
],
[
[
1010,
23,
112
],
[
112,... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Sevoflurane and Sevoflurane (Compound) resembles Perflutren (Compound)
Mefloquine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Perflutren (Compound)
Mefloquine may cause a minor interaction that ... |
DB00981 | DB01100 | 1,528 | 1,568 | [
"DDInter1462",
"DDInter1470"
] | Physostigmine | Pimozide | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
1528,
24,
1568
]
],
[
[
1528,
21,
29356
],
[
29356,
60,
1568
]
],
[
[
1528,
63,
19
],
[
19,
24,
1568
]
],
[
[
1528,
24,
830
],
[
830,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Salivary hypersecretion"
],
[
"Salivary hypersecretion",
... | Physostigmine (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Pimozide (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbat... |
DB00679 | DB04868 | 684 | 478 | [
"DDInter1796",
"DDInter1293"
] | Thioridazine | Nilotinib | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
684,
25,
478
]
],
[
[
684,
6,
6017
],
[
6017,
45,
478
]
],
[
[
684,
7,
6717
],
[
6717,
46,
478
]
],
[
[
684,
18,
8587
],
[
8587,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilo... | Thioridazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Thioridazine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Nilotinib (Compound)
Thioridazine (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Nilotinib (Compound)
Thioridazin... |
DB00927 | DB12161 | 1,559 | 730 | [
"DDInter712",
"DDInter512"
] | Famotidine | Deutetrabenazine | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
1559,
24,
730
]
],
[
[
1559,
62,
112
],
[
112,
23,
730
]
],
[
[
1559,
63,
322
],
[
322,
24,
730
]
],
[
[
1559,
24,
971
],
[
971,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin an... |
DB00398 | DB08899 | 79 | 129 | [
"DDInter1702",
"DDInter649"
] | Sorafenib | Enzalutamide | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
79,
24,
129
]
],
[
[
79,
24,
918
],
[
918,
1,
129
]
],
[
[
79,
6,
8374
],
[
8374,
45,
129
]
],
[
[
79,
7,
16629
],
[
16629,
46,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Sorafenib (Compound) upregulates RPL39L (Gene) and RPL39L (G... |
DB00372 | DB00835 | 999 | 100 | [
"DDInter1793",
"DDInter245"
] | Thiethylperazine | Brompheniramine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
999,
24,
100
]
],
[
[
999,
24,
128
],
[
128,
24,
100
]
],
[
[
999,
24,
211
],
[
211,
63,
100
]
],
[
[
999,
63,
1594
],
[
1594,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbromphe... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when... |
DB00176 | DB04845 | 529 | 309 | [
"DDInter770",
"DDInter1001"
] | Fluvoxamine | Ixabepilone | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
529,
24,
309
]
],
[
[
529,
6,
8374
],
[
8374,
45,
309
]
],
[
[
529,
18,
16974
],
[
16974,
45,
309
]
],
[
[
529,
21,
28736
],
[
28736,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Fluvoxamine (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Ixabepilone (Compound)
Fluvoxamine (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
... |
DB01068 | DB09054 | 1,565 | 384 | [
"DDInter411",
"DDInter905"
] | Clonazepam | Idelalisib | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1565,
24,
384
]
],
[
[
1565,
24,
222
],
[
222,
23,
384
]
],
[
[
1565,
63,
58
],
[
58,
24,
384
]
],
[
[
1565,
24,
259
],
[
259,
2... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Aleface... |
DB06603 | DB09039 | 39 | 1,670 | [
"DDInter1387",
"DDInter629"
] | Panobinostat | Eliglustat | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
39,
25,
1670
]
],
[
[
39,
62,
479
],
[
479,
23,
1670
]
],
[
[
39,
64,
121
],
[
121,
24,
1670
]
],
[
[
39,
25,
1409
],
[
1409,
24... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Panobinostat may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may caus... |
DB01035 | DB06663 | 1,401 | 1,154 | [
"DDInter1524",
"DDInter1398"
] | Procainamide | Pasireotide | A derivative of procaine with less CNS action. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1401,
25,
1154
]
],
[
[
1401,
63,
966
],
[
966,
40,
1154
]
],
[
[
1401,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1401,
62,
112
],
[
112... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octre... | Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Procainamide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Procainamide may cause a min... |
DB08870 | DB10989 | 850 | 496 | [
"DDInter228",
"DDInter858"
] | Brentuximab vedotin | Hepatitis A Vaccine | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
850,
24,
496
]
],
[
[
850,
63,
4
],
[
4,
24,
496
]
],
[
[
850,
24,
738
],
[
738,
63,
496
]
],
[
[
850,
24,
1480
],
[
1480,
24,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Brentuximab vedotin may cause a moderate interaction that could ... |
DB01211 | DB06595 | 609 | 1,491 | [
"DDInter393",
"DDInter1214"
] | Clarithromycin | Midostaurin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
609,
25,
1491
]
],
[
[
609,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
609,
62,
112
],
[
112,
23,
1491
]
],
[
[
609,
24,
761
],
[
761,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Clarithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole m... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.